Recent News Releases

Mar 18, 2019

InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of...

Mar 13, 2019

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program

Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success Initiation of a Phase I Clinical Trial Remains On-track TSX:IN OTCQX:IMLFF VANCOUVER, March 13, 2019...

Mar 12, 2019

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of...

Mar 6, 2019

InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

TSX:IN OTCQX:IMLFF Dinh Fortifies InMed's Development Expertise in Dermatology and Drug Delivery VANCOUVER, March 6, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN;...

See All News Releases

Latest Presentation

Unlocking the Potential of Cannabinoid Medicines

March 17-19, 2019

Download pdf

Letter to Shareholders

Annual Letter to Shareholders 2019

January 31, 2019

Download pdf

Company Fact Sheet

Company Fact Sheet

April, 2019

Download pdf

	Fact Sheet (518 KB)

SEDAR^® Filings

Loading data...

Financial Reports

Quarterly and Annual Financial Results

2019

Second quarter, 2019 (quarter ended December 31, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A

First quarter, 2019 (quarter ended September 30, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A

2018

AGM Documents

• Notice of AGM and Information (Proxy) Circular
• Form of Proxy

Fourth quarter, 2018 (full year ended June 30, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A
• Annual Information Form

Third quarter, 2018 (quarter ended March 31, 2018)

• Quarterly Press Release
• Financial Statements
• MD&A

Second quarter, 2018 (quarter ended December 31, 2017)

• Financial Statements
• MD&A

First quarter, 2018 (quarter ended September 30, 2017)

• Financial Statements
• MD&A

2017

Fourth quarter, 2017 (full year ended June 30, 2017)

• Financial Statements
• MD&A
• Annual Information Form
• Letter from the President and Chief Executive Officer

Third quarter, 2017 (quarter ended March 31, 2017)

• Financial Statements
• MD&A

Second quarter, 2017 (quarter ended December 31, 2016)

• Financial Statements
• MD&A

First quarter, 2017 (quarter ended September 30, 2016)

• Financial Statements
• MD&A

Stock Performance

OTCQX: IMLFFTSX: IN

1d

5d

1m

3m

6m

YTD

1y

5y

10y

-

Loading...

Display Events

 

Dividends

 

Splits

 

Earnings

 

News

Chart Style

Line

Mountain

OHLC

Candlestick

Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings Events data provided by Wall Street Horizon.

OTCQX: IMLFFTSX: IN

Analyst Coverage

Firm	Analyst	E-mail	Phone
Edison Investment Research	Maxim Jacobs	MJacobs@edisongroup.com	+1 (646) 653-7027
ROTH Capital Partners	Jerry Isaacson, Ph.D.	jisaacson@roth.com	+1 (406) 425-0563